Home LiteratureArticle Details
PMID: 1157430 Published · ppublish English Journal Article

Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.

Clinical neurology and neurosurgery ·Vol. 78 ·No. 1 ·1975-00-00 ·Pages 59-72

Hommes OR, Prick JJ, Lamers KJ

Abstract

32 patients with the chronic progressive form of the multiple sclerosis were treated with high doses of cyclophosphamide and prednisone during 20 days, to produce immunosuppression. The effect of treatment was measured by scoring three different Kurtzke scales just before treatment (1), just after treatment (II), and 3 months after treatment (III). The results indicate that in the treatment period I to II most patients improve, some dramatically. The improvement continues in 15 of 25 patients scored between 6 and 33 months after treatment. Better results were found in patients with shorter duration of their disease. More improvement is found as the IgG percentage of the spinal fluid at I is higher. The improvement is less when the initial condition (I) is more serious.

MeSH Terms
Adult Cyclophosphamide/adverse effects,therapeutic use Drug Therapy, Combination Female Humans Immunoglobulin G/analysis Male Middle Aged Multiple Sclerosis/blood,cerebrospinal fluid,drug therapy Prednisone/adverse effects,therapeutic use
Chemicals
Immunoglobulin G Cyclophosphamide Prednisone
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Hommes O R
Prick J J
Lamers K J
Article Info
Journal
Clinical neurology and neurosurgery
Abbr.
Clin Neurol Neurosurg
ISSN
0303-8467
Published
1975-00-00
Pages
59-72
Language
English
Region
Netherlands
NLM ID
7502039
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]